search for


Ticagrelor does not affect left ventricular remodeling following acute myocardial ischemia
Med Biol Sci Eng 2021;4(1):34-41
Published online January 31, 2021
© 2021 Medical Biological Science and Engineering.

Hyun Kuk Kim1*, Kyung Seob Lim2*, Sung Soo Kim1 , Joo-Young Na3

1Department of Cardiovascular Medicine, Chosun University Medical School, Gwangju, 2Futuristic Animal Resource and Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, 3Department of Pathology, Pusan National University Yangsan Hospital, Yangsan, Korea
Correspondence to: Sung Soo Kim
Department of Cardiovascular Medicine, Chosun University Medical School, 365 Pilmun-daero, Dong-gu, Gwangju 61452, Korea
Tel: +82-62-220-3240
Fax: +82-62-228-7174

*These authors (Hyun Kuk Kim and Kyung Seob Lim) contributed equally to this work.
Received December 1, 2020; Revised December 11, 2020; Accepted December 15, 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despite ticagrelor’s proven superiority to clopidogrel in treating patients with acute coronary syndrome, it is unclear whether its actions are mediated by antiplatelet inhibition or by some other pleotropic effect. In this study, we used a porcine model of acute myocardial infarction (AMI) to evaluate the efficacy of ticagrelor administered at a similar level of platelet inhibition to that seen with clopidogrel. Twenty pigs were grouped according to the P2Y12-receptor inhibitors (ticagrelor or clopidogrel). Platelet inhibition was monitored by measuring adenosine diphosphate - induced platelet aggregation. A chronic ischemic heart model was artificially generated by embolization of the middle left anterior descending coronary artery. Animals received a maintenance dose of the antiplatelet agents. Two-dimensional echocardiography was performed on the surviving animals 2 weeks later. Both 180 mg ticagrelor and 600 mg clopidogrel exerted a significant and consistent antiplatelet effect showing platelet aggregation inhibition of 50.7±22.9% and 45.5±21.0%, respectively, p=0.614), which persisted for up to 2 weeks. However, no significant differences were observed in ventricular arrhythmia (40% vs. 50%, respectively; p=0.886). The ejection fraction measured 2 weeks after surgery was 44.6± 7.4% in the ticagrelor group and 36.9±5.7% in the clopidogrel group (p=0.091). In a chronic ischemic heart failure model with a similar level of platelet inhibition, ticagrelor was no better than clopidogrel in reducing mortality and improving cardiac function.
Keywords : Myocardial infarction; Cardiac arrhythmia; Antiplatelet agent
  1. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007;100:27-40.
    Pubmed CrossRef
  2. Cayla G, Montalescot G, Collet JP. Ticagrelor to prevent restenosis: new drug for an old hypothesis? Arterioscler Thromb Vasc Biol 2010;30:2320-2.
    Pubmed CrossRef
  3. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
  4. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
    Pubmed CrossRef
  5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
    Pubmed CrossRef
  6. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 2014;35:2083-93.
    Pubmed KoreaMed CrossRef
  7. Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol 2014;34:2078-85.
    Pubmed CrossRef
  8. Ye Y, Birnbaum GD, Perez-Polo JR, Nanhwan MK, Nylander S, Birnbaum Y. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol 2015;35:1805-14.
    Pubmed CrossRef
  9. Vilahur G, Gutiérrez M, Casani L, Varela L, Capdevila A, Pons-Lladó G, et al. Protective effects of ticagrelor on myocardial injury after infarction. Circulation 2016;134:1708-19.
    Pubmed CrossRef
  10. Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circ J 2015;79:2452-60.
    Pubmed CrossRef
  11. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:1524-34.
    Pubmed CrossRef
  12. Huang CC, Tsai HW, Lee WY, Lin WW, Chen DY, Hung YW, et al. A translational approach in using cell sheet fragments of autologous bone marrow-derived mesenchymal stem cells for cellular cardiomyoplasty in a porcine model. Biomaterials 2013;34:4582-91.
    Pubmed CrossRef
  13. Bloch Thomsen PE, Jons C, Raatikainen MJ, Moerch Joergensen R, Hartikainen J, Virtanen V, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation 2010;122:1258-64.
    Pubmed CrossRef
  14. Kim YS, Kim NY, Bae IH, Park JK, Park DS, Shim JW, et al. Novel porcine model of acute myocardial infarction using polyethylene terephthalate. J Biomed Transl Res 2019;20:44-52.
  15. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-84.
    Pubmed CrossRef
  16. Wang C, Zhao G, Wang X, Nie S. Effect of potent P2Y12 inhibitors on ventricular arrhythmias and cardiac dysfunction in coronary artery disease: a systematic review and meta-analysis. Biomed Res Int 2018;2018:8572740.
    Pubmed KoreaMed CrossRef
  17. Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, et al. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 2016;102:617-25.
    Pubmed CrossRef
  18. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-54.
    Pubmed CrossRef

July 2022, 5 (2)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)

Funding Information
  • Crossref
  • Google Scholar